{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302727677.html", "message": "News view counter 632020 successfully enlarged"}